Total Payments
$2,383
2024 Payments
$287.26
Companies
25
Transactions
138
Medicare Patients
3,441
Medicare Billing
$927,997
Payment Breakdown by Category
Food & Beverage$2,354 (98.8%)
Other$29.57 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,354 | 136 | 98.8% |
| Debt forgiveness | $29.57 | 2 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $710.77 | 49 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $249.68 | 14 | $0 (2024) |
| Gilead Sciences, Inc. | $210.98 | 11 | $0 (2024) |
| Janssen Biotech, Inc. | $185.06 | 11 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $182.59 | 9 | $0 (2023) |
| GENZYME CORPORATION | $158.63 | 7 | $0 (2023) |
| Celgene Corporation | $125.14 | 8 | $0 (2024) |
| Boston Scientific Corporation | $84.12 | 2 | $0 (2022) |
| Ferring Pharmaceuticals Inc. | $48.50 | 3 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $47.20 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $287.26 | 16 | ABBVIE INC. ($68.48) |
| 2023 | $803.69 | 44 | ABBVIE INC. ($189.44) |
| 2022 | $890.54 | 48 | ABBVIE INC. ($232.64) |
| 2021 | $287.91 | 23 | AbbVie Inc. ($205.20) |
| 2020 | $16.66 | 1 | QOL Medical, LLC ($16.66) |
| 2019 | $82.02 | 5 | Covidien LP ($23.42) |
| 2017 | $15.01 | 1 | AbbVie, Inc. ($15.01) |
All Payment Transactions
138 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/08/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: LIVER DISEASE | ||||||
| 10/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: LIVER DISEASE | ||||||
| 07/22/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 07/12/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/15/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/10/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.64 | General |
| Category: Neuroscience | ||||||
| 04/08/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 03/09/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: IMMUNOLOGY | ||||||
| 02/21/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/19/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.02 | General |
| 02/01/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.06 | General |
| 01/31/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | CYLTEZO (Biological) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: CNS | ||||||
| 01/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.60 | General |
| 12/22/2023 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $17.98 | General |
| 12/07/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: Immunology | ||||||
| 11/17/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | CYLTEZO (Drug) | Food and Beverage | In-kind items and services | $29.28 | General |
| Category: CNS | ||||||
| 11/14/2023 | ABBVIE INC. | LINZESS (Drug), CREON, VIBERZI | Food and Beverage | In-kind items and services | $9.72 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/09/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: Gastroenterology | ||||||
| 10/27/2023 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/13/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/10/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.37 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 893 | 8,620 | $1.1M | $231,839 |
| 2022 | 22 | 941 | 10,040 | $1.2M | $265,792 |
| 2021 | 21 | 847 | 10,521 | $1.1M | $259,374 |
| 2020 | 24 | 760 | 6,172 | $720,700 | $170,991 |
Total Patients
3,441
Total Services
35,353
Medicare Billing
$927,997
Procedure Codes
89
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 20 | 6,301 | $239,438 | $108,952 | 45.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 22 | 1,410 | $197,400 | $36,799 | 18.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 129 | 133 | $162,539 | $24,998 | 15.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 152 | 154 | $175,170 | $13,605 | 7.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 111 | 113 | $106,071 | $8,536 | 8.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 60 | 61 | $20,069 | $5,847 | 29.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 63 | 96 | $17,313 | $5,577 | 32.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 43 | $13,115 | $3,839 | 29.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $10,611 | $3,298 | 31.1% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 48 | 48 | $35,120 | $3,174 | 9.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 18 | 18 | $16,398 | $2,721 | 16.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 38 | 44 | $9,416 | $2,673 | 28.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 24 | 26 | $8,658 | $2,351 | 27.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 15 | 15 | $13,665 | $2,311 | 16.9% |
| 43237 | Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope through mouth | Facility | 2023 | 17 | 18 | $14,112 | $2,017 | 14.3% |
| 43238 | Ultrasound guided needle aspiration or biopsy of esophagus using a flexible endoscope | Facility | 2023 | 13 | 13 | $12,155 | $1,915 | 15.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 13 | 13 | $3,406 | $1,062 | 31.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 22 | 23 | $5,267 | $968.98 | 18.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 15 | 16 | $2,112 | $549.21 | 26.0% |
| 43450 | Dilation of esophagus | Facility | 2023 | 12 | 12 | $5,749 | $345.59 | 6.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 33 | 36 | $468.00 | $302.40 | 64.6% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 20 | 7,200 | $273,600 | $123,948 | 45.3% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 24 | 1,890 | $264,600 | $54,102 | 20.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 134 | 136 | $164,660 | $24,692 | 15.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 149 | 150 | $160,255 | $12,906 | 8.1% |
About Dr. Jordan Holmes, MD
Dr. Jordan Holmes, MD is a Gastroenterology healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/09/2008. The National Provider Identifier (NPI) number assigned to this provider is 1518130624.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jordan Holmes, MD has received a total of $2,383 in payments from pharmaceutical and medical device companies, with $287.26 received in 2024. These payments were reported across 138 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($2,354).
As a Medicare-enrolled provider, Holmes has provided services to 3,441 Medicare beneficiaries, totaling 35,353 services with total Medicare billing of $927,997. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology, Student in an Organized Health Care Education/Training Program
- Location Omaha, NE
- Active Since 04/09/2008
- Last Updated 02/19/2019
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1518130624
Products in Payments
- ENTYVIO (Biological) $229.66
- CREON (Drug) $223.95
- DUPIXENT (Biological) $205.83
- LINZESS (Drug) $139.04
- ZEPOSIA (Drug) $125.14
- XIFAXAN (Drug) $123.72
- RINVOQ (Biological) $107.25
- HUMIRA (Biological) $107.00
- REMICADE (Biological) $106.54
- EXALT Model D (Device) $84.12
- STELARA (Biological) $78.52
- SKYRIZI (Biological) $53.74
- OCALIVA (Drug) $46.22
- RESMETIROM (Drug) $44.34
- TRULANCE (Drug) $42.98
- VIBERZI (Drug) $39.96
- Linzess (Drug) $34.47
- CLENPIQ (Drug) $30.99
- DIFICID (Drug) $30.00
- CYLTEZO (Drug) $29.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Omaha
Rowen Zetterman, Md, MD
Gastroenterology — Payments: $150,426
Gastroenterology $150,426
Sandeep Mukherjee, Md, MD
Gastroenterology — Payments: $146,207
Gastroenterology $146,207
Benjamin Hall, Md, MD
Gastroenterology — Payments: $124,195
Gastroenterology $124,195
Peter Mannon, M.d, M.D
Gastroenterology — Payments: $110,607
Gastroenterology $110,607
Dr. Kimberly Harmon, Md, MD
Gastroenterology — Payments: $35,200
Gastroenterology $35,200
Dr. Grant Hutchins, Md, MD
Gastroenterology — Payments: $17,175
Gastroenterology $17,175